Correspondence 0001437749-25-011033 from Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc.
Date: April 4, 2025 · CIK: 0001659617 · Accession: 0001437749-25-011033
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286276
Letter
mbrx20250404_corresp.htm
Moleculin Biotech, Inc.
5300 Memorial Drive, Suite 950
Houston, TX 77007
April 4, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Attention: Alan Campbell
Re:
Moleculin Biotech, Inc.
Registration Statement on Form S-1
Registration No. 333-286276
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 P.M. (Eastern Time) on April 7, 2025, or as soon thereafter as possible on such date.
Very truly yours,
Moleculin Biotech, Inc.
Show Raw Text
CORRESP 1 filename1.htm mbrx20250404_corresp.htm Moleculin Biotech, Inc. 5300 Memorial Drive, Suite 950 Houston, TX 77007 April 4, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attention: Alan Campbell Re: Moleculin Biotech, Inc. Registration Statement on Form S-1 Registration No. 333-286276 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 P.M. (Eastern Time) on April 7, 2025, or as soon thereafter as possible on such date. Very truly yours, Moleculin Biotech, Inc. By: /s/ Jonathan P. Foster Name: Jonathan P. Foster Title: Chief Financial Officer